Search results
Bristol-Myers Squibb Co. [BMY] Records 50-Day SMA of $48.20 – Knox Daily
Knox Daily· 20 hours agoInvestors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Bristol-Myers Squibb Co. shares valued ...
Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 79%
Simply Wall St. via Yahoo Finance· 6 days agoKey Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price...
This Unpopular Dividend Stock Is a Buy
The Motley Fool via AOL· 16 hours agoThe drugmaker's shares are down by over 17% year to date and over 33% over the prior 12 months. Despite one of the richest dividend yields in the sector...
A Guide To The Risks Of Investing In Bristol-Myers Squibb Co.
Knox Daily· 4 days ago[BMY] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Redburn Atlantic’s analysts, who decreased its forecast ...
1 Stock I Wouldn't Touch With a 10-Foot Pole
Motley Fool via Yahoo Finance· 3 days agoThere are many positive things about Bristol Myers Squibb (NYSE: BMY) and its stock. It has a decently high dividend yield, it's one of the world's...
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity - Bristol-Myers Squibb...
Benzinga· 2 days agoVolume & Open Interest Development Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest ...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks via Yahoo Finance· 1 day agoConcurrent with the first-quarter earnings release, Bristol Myers also announced that it is...
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To...
Benzinga via AOL· 1 day agoA judge in Hawaii has reportedly ordered Bristol Myers Squibb & Co (NYSE:BMY) and Sanofi SA...
This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a...
CNBC· 12 hours agoBig pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall...
Erasca restructures; Novartis moves to complete MorphoSys deal
BioPharma Dive via Yahoo Finance· 7 days agoThe cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere,...
